169 related articles for article (PubMed ID: 25070259)
21. Dual mechanisms of 9-beta-D-arabinofuranosylguanine resistance in CEM T-lymphoblast leukemia cells.
Curbo S; Zhu C; Johansson M; Balzarini J; Karlsson A
Biochem Biophys Res Commun; 2001 Jul; 285(1):40-5. PubMed ID: 11437369
[TBL] [Abstract][Full Text] [Related]
22. Arabinosyl nucleosides. XXXII. Mechanism of inhibition of L5178y mouse lymphoma cells by 9-beta-D-arabinofuranosylguanine.
Müller WE; Geurtsen W; Beyer R; Schuster DK; Zahn RK; Arendes J
Chem Biol Interact; 1981 Mar; 34(3):301-13. PubMed ID: 7460088
[TBL] [Abstract][Full Text] [Related]
23. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
24. Low level of mitochondrial deoxyguanosine kinase is the dominant factor in acquired resistance to 9-beta-D-arabinofuranosylguanine cytotoxicity.
Lotfi K; Månsson E; Peterson C; Eriksson S; Albertioni F
Biochem Biophys Res Commun; 2002 May; 293(5):1489-96. PubMed ID: 12054684
[TBL] [Abstract][Full Text] [Related]
25. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.
Lambe CU; Averett DR; Paff MT; Reardon JE; Wilson JG; Krenitsky TA
Cancer Res; 1995 Aug; 55(15):3352-6. PubMed ID: 7614470
[TBL] [Abstract][Full Text] [Related]
26. Changes in intracellular activation-related gene expression and induction of Akt contribute to acquired resistance toward nelarabine in CCRF-CEM cell line.
Rindiarti A; Okamoto Y; Nakagawa S; Hirose J; Kodama Y; Nishikawa T; Kawano Y
Leuk Lymphoma; 2022 Feb; 63(2):404-415. PubMed ID: 35080473
[TBL] [Abstract][Full Text] [Related]
27. Nelarabine.
Sanford M; Lyseng-Williamson KA
Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
[TBL] [Abstract][Full Text] [Related]
28. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
Reilly KM; Kisor DF
Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
[TBL] [Abstract][Full Text] [Related]
29. Metabolism and selectivity of arabinonucleoside in human lymphoid cells.
Fridland A; Verhoef V
Proc Soc Exp Biol Med; 1985 Sep; 179(4):456-62. PubMed ID: 2991939
[TBL] [Abstract][Full Text] [Related]
30. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.
Xie C; Plunkett W
Cancer Res; 1995 Jul; 55(13):2847-52. PubMed ID: 7540950
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
32. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
33. Differential incorporation of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosylguanine into nuclear and mitochondrial DNA.
Zhu C; Johansson M; Karlsson A
FEBS Lett; 2000 Jun; 474(2-3):129-32. PubMed ID: 10838071
[TBL] [Abstract][Full Text] [Related]
34. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.
Adema AD; Losekoot N; Smid K; Kathmann I; Myhren F; Sandvold ML; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):394-9. PubMed ID: 20544525
[TBL] [Abstract][Full Text] [Related]
35. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
36. Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells.
Takagaki K; Katsuma S; Kaminishi Y; Horio T; Nakagawa S; Tanaka T; Ohgi T; Yano J
J Biochem; 2004 Nov; 136(5):733-40. PubMed ID: 15632314
[TBL] [Abstract][Full Text] [Related]
37. Activation of guanine-β-D-arabinofuranoside and deoxyguanosine to triphosphates by a common pathway blocks T lymphoblasts at different checkpoints.
Leanza L; Miazzi C; Ferraro P; Reichard P; Bianchi V
Exp Cell Res; 2010 Dec; 316(20):3443-53. PubMed ID: 20603113
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez CO; Ramakrishna P; Rosner GL; Hodge JP; O'Brien S; Keating MJ
J Clin Oncol; 2001 Apr; 19(8):2142-52. PubMed ID: 11304766
[TBL] [Abstract][Full Text] [Related]
39. Analysis of DNA methylation of the 5' region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)-resistant cells.
Leegwater PA; De Abreu RA; Albertioni F
Cancer Lett; 1998 Aug; 130(1-2):169-73. PubMed ID: 9751270
[TBL] [Abstract][Full Text] [Related]
40. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
